Granules India Gets US FDA's Voluntary Action Indicated Classification for Bonthapally, India Unit

MT Newswires Live

10/29

Pharmaceutical manufacturing company Granules India (NSE:GRANULES, BOM:532482) received an establishment inspection report (EIR) with an inspection classification of voluntary action indicated (VAI) for its facility at Bonthapally in Hyderabad, India, according to a Wednesday filing to the Indian stock exchanges.

The company had received one observation from the US FDA after the inspection of its active pharmaceutical ingredients (API) facility conducted in June. The company had submitted its response within the stipulated time.

The facility manufactures Paracetamol API. It also has Metformin and Guaifenesin API manufacturing plants in the same facility.

The company's shares were up over 1% in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579240379"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579240379\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579240379?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 16:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579240379","market":"nz","top_or_hot":-1,"title":"Granules India Gets US FDA's Voluntary Action Indicated Classification for Bonthapally, India Unit","media":"MT Newswires Live","content":"<html><body><p> Pharmaceutical manufacturing company Granules India (NSE:GRANULES, BOM:532482) received an establishment inspection report (EIR) with an inspection classification of voluntary action indicated (VAI) for its facility at Bonthapally in Hyderabad, India, according to a Wednesday filing to the Indian stock exchanges.</p><p>The company had received one observation from the US FDA after the inspection of its active pharmaceutical ingredients (API) facility conducted in June. The company had submitted its response within the stipulated time.</p><p>The facility manufactures Paracetamol API. It also has Metformin and Guaifenesin API manufacturing plants in the same facility.</p><p>The company's shares were up over 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Granules India Gets US FDA's Voluntary Action Indicated Classification for Bonthapally, India Unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGranules India Gets US FDA's Voluntary Action Indicated Classification for Bonthapally, India Unit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-29 16:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Pharmaceutical manufacturing company Granules India (NSE:GRANULES, BOM:532482) received an establishment inspection report (EIR) with an inspection classification of voluntary action indicated (VAI) for its facility at Bonthapally in Hyderabad, India, according to a Wednesday filing to the Indian stock exchanges.</p><p>The company had received one observation from the US FDA after the inspection of its active pharmaceutical ingredients (API) facility conducted in June. The company had submitted its response within the stipulated time.</p><p>The facility manufactures Paracetamol API. It also has Metformin and Guaifenesin API manufacturing plants in the same facility.</p><p>The company's shares were up over 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2579240379","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579240379","pubTimestamp":1761726140,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pharmaceutical manufacturing company Granules India  received an establishment inspection report  with an inspection classification of voluntary action indicated  for its facility at Bonthapally in Hyderabad, India, according to a Wednesday filing to the Indian stock exchanges.The company had received one observation from the US FDA after the inspection of its active pharmaceutical ingredients  facility conducted in June. The company had submitted its response within the stipulated time.The facility manufactures Paracetamol API. It also has Metformin and Guaifenesin API manufacturing plants in the same facility.The company's shares were up over 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4503":"景林资产持仓","OTX.SI":"迈怡汇有限公司","BK6520":"工商业服务概念","API.AU":"Australian Pharma Industries","BK4023":"应用软件","BK4551":"寇图资本持仓","BK6100":"保健护理服务","API":"声网","BK7103":"保健护理产品经销商"},"translate_title":"印度颗粒获得美国FDA对印度Bonthapally工厂的自愿行动指示分类","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"API":1,"API.AU":1,"MNDmain":1.5,"OTX.SI":0.9},"content_text":"Pharmaceutical manufacturing company Granules India (NSE:GRANULES, BOM:532482) received an establishment inspection report (EIR) with an inspection classification of voluntary action indicated (VAI) for its facility at Bonthapally in Hyderabad, India, according to a Wednesday filing to the Indian stock exchanges.The company had received one observation from the US FDA after the inspection of its active pharmaceutical ingredients (API) facility conducted in June. The company had submitted its response within the stipulated time.The facility manufactures Paracetamol API. It also has Metformin and Guaifenesin API manufacturing plants in the same facility.The company's shares were up over 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}